Obstructive Hypertrophic Cardiomyopathy: The Role of Septal Reduction Therapy in the Current Era of Cardiac Myosin Inhibitors

Drs. Maron and Rowin review how treatment for symptomatic obstructive hypertrophic cardiomyopathy has evolved from mainly using beta blockers and invasive procedures to now including newer cardiac myosin inhibitor drugs. These newer medications more reliably reduce obstruction and improve patient symptoms and exercise capacity, but require careful safety monitoring with regular heart function checks.